Literature DB >> 10568575

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

R C Cook, J M Connors, R D Gascoyne, G Fradet, R D Levy.   

Abstract

Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD20 monoclonal antibody. Treatment resulted in two complete remissions and one non-response.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10568575     DOI： 10.1016/S0140-6736(99)02058-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

Authors:  J M Boulter; B K Jakobsen
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 2.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

3.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 4.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 5.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

6.  Pulmonary nodules and masses in lung transplant recipients: clinical and CT findings.

Authors:  Olivier Morla; Renan Liberge; Pierre Paul Arrigoni; Eric Frampas
Journal:  Eur Radiol       Date:  2014-06-05       Impact factor: 5.315

Review 7.  Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.

Authors:  Vidhya Murukesan; Sandeep Mukherjee
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

8.  Comparative pathobiology of macaque lymphocryptoviruses.

Authors:  Angela Carville; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

9.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 10.  The post-transplant lymphoproliferative disorder-a literature review.

Authors:  Rokshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.